Novartis Gets Funds From Bill & Melinda Gates Foundation to Treat Cryptosporidiosis
February 14 2018 - 2:04AM
Dow Jones News
By Marc Bisbal Arias
Novartis AG (NOVN.EB) said Wednesday that it has signed an
alliance with the Bill & Melinda Gates Foundation for further
development of a drug that treats the diarrheal disease
cryptosporidiosis.
The Swiss company said that the Gates Foundation will provide
$6.5 million to support the development of Novartis's drug
candidate KDU731.
"Cryptosporidiosis is the second leading cause of infectious
diarrhea in children under two years of age," Novartis said.
Diarrheal diseases cause around 525,000 deaths a year.
Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com
(END) Dow Jones Newswires
February 14, 2018 01:49 ET (06:49 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024